病理学与病理生理学 教授
职称：教授
学科专业：病理学与病理生理学
研究方向：
团队专注于1）探索癌症病因（为何）和机制（如何）；2）并开展新型诊疗靶点靶标的转化研究和研发。1）目前靶向药物的靶点主要是癌基因突变，但相当多的肿瘤患者并不能从中获益。我们提出“突变非依赖肿瘤”假说，并发现“RNA异常剪接”是环境和肿瘤之间的一种“桥梁”机制，并证实剪接产物“嵌合RNA”和“嵌合蛋白”在肿瘤演化中起驱动作用。基于上述新的机制，我们建立了一系列相应的平台（外泌体平台、嵌合抗体、双特异抗体等），开展了新型治疗靶点和早筛早诊靶标的转化研究和研发，包括外泌体液体活检早筛早诊和外泌体肿瘤疫苗等，并开展了多项临床试验；2）针对酪氨酸磷酸酶(PTPs)（抑癌基因）不能成药的瓶颈，发现PTPs在肿瘤耐药和化疗脑中的新机制，并建立RNA激活平台，研发工程化外泌体抗体导向RNA激活药物解决PTPs不能成药的困境。
行政职务：肿瘤精准医学和病理研究所所长、教育部肿瘤分子生物学重点实验室副主任
电子邮箱：haozhang@jnu.edu.cn
个人介绍：
张灏教授，暨南大学医学院教授、博士生导师、博士后指导教授、肿瘤精准医学和病理研究所所长、教育部肿瘤分子生物学重点实验室副主任，Annals of Medicine（Taylor & Francis出版社）肿瘤学主编。专注我国高发恶性肿瘤的诊治的转化研究和应用，1）发现RNA异常剪接及其产物（嵌合RNA和嵌合蛋白）作为“突变非依赖肿瘤”驱动机制，并以此为诊断靶标和治疗靶点开展了外泌体液体活检和免疫治疗，包括无创性唾液外泌体检测、基于嵌合RNA的外泌体疫苗；2）酪氨酸磷酸酶(PTPs)抑癌基因在肿瘤中的调控机制和治疗靶点，克服PTPs不能成药的瓶颈研发外泌体包裹的抗体导向RNA激活药物。近年来以通讯作者发表学术成果，包括PNAS（两篇）、Clin Cancer Research （两篇）、Gastroenterology、Mol Cancer、Oncogene（两篇）、JCI insight、Drug Resistant Update、J Pathology等。获批十余项发明专利，荣获2021年《广东省科技进步奖二等奖》、2019年及2024年获得《广东省医学科技奖二等奖》、2023年《河南省科技进步一等奖》、2021年《中国产学研合作创新奖》、2021年《金博奖全球高层人才科技创新大赛金奖》、2021年《全国十佳消化道领域临床研究金奖》、2023年《中国研究型医院学会医学研究创新奖一等奖》、《Wiley中国开放科学高贡献奖》、《2022中国生物医药企业最具创新力50强奖》等。担任中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会（CSEMV）主委，《外泌体研究转化和临床应用专家共识》专家组组长。Cancer Letters（Elsevier 出版社）编委，Extracellular Vesicles & Circulating Nucleic Acids（OAE 出版社）编委，Extracellular Vesicle （Elsevier出版社）编委，Scientific Report（Nature出版社）编委。中国抗癌协会肿瘤标志专业委员会常务委员，中国抗癌协会肿瘤标志物专业委员会常委，中国抗癌协会肿瘤代谢委员会常委，中国临床肿瘤协会胰腺癌专家委员会常委，亚太医学生物免疫学会肿瘤学分会副主委，广东省抗癌协会肿瘤代谢委员会副主委，广东省抗癌协会肿瘤标志物专业委员会副主委, 广东省抗癌协会抗肿瘤药物专业委员会副主委。
1.1994-1999，日本岛根医科大学，博士，发育生物学/细胞生物学
2.1988-1994，中国医科大学附属盛京医院，住院医/主治医/讲师，内科内分泌科
3.1984-1987，中国医科大学，硕士，内科内分泌学
4.1979-1984，中国医科大学，本科，临床医学
1.2018-至今，暨南大学，基础医学与公共卫生学院教授、肿瘤精准医学和病理研究所所长、教育部肿瘤分子生物学重点实验室副主任
2.2008-2018，汕头大学医学院，教授，附属肿瘤医院/肿瘤研究中心
3.2004-2008，美国UT MD Anderson 癌症中心，讲师，分子肿瘤学系/遗传系
4.1999-2004，美国贝勒医学院，博士后研究员，分子细胞学系
※特邀综述和社论(*通讯作者)
1.Lin Y#,Wang S#,Bremer E*,Zhang H*.Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low‐dose metformin. Cancer Commun (Lond).2021 Aug;41(8):637-641.（EDITORIAL）
2.Wang S#,Lin Y#,Tang H,Cai S,Qiu X,Pan Y,Zhang H*. Exosome-based liquid biopsy: Opportunities and challenges for changing patient care of gastrointestinal cancers.Esophageal Cancer.2023(01):59-73.
3.Chang L#,Ni J#,Zhu Y,Pang B,Graham P,Zhang H*,Li Y*.Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics.2019 May 31;9(14):4130-4140.
4.Zheng L#,Wang L#,Gan J,Zhang H*.RNA activation:promise as a new weapon against cancer. Cancer lett. 2014 Dec 1;355(1):18-24.
5.Ning Z,Gan J,Chen C,Zhang D,Zhang H*.Molecular functions and significance of the MTA family in hormone-independent cancer.Cancer Metastasis Rev. 2014 Dec;33(4):901-919.
6.Su J,Concilla A,Zhang D,Zhao F,Shen F,Zhang H*,Zhou F*.PIWI-interacting RNAs:Mitochondria-based Biogenesis and Functions in Cancer.Genes Dis. 2020 Oct 5;8(5):603-622.
7.Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P, Li Y*.Exosomes and breast cancer drug resistance. Cell Death Dis. 2020 Nov 17;11(11):987.
8.Chu YL,Li H,Ng PLA,Kong ST,Zhang H,Lin Y,Tai WCS,Yu ACS,Yim AKY,Tsang HF,Cho WCS,Wong SCC*.The potential of circulating exosomal RNA biomarkers in cancer.Expert Rev Mol Diagn. 2020 Jul;20(7):665-678.
9.Ma L,Yao Z,Deng W,Zhang D,Zhang H*.The Many Faces of MTA3 Protein in Normal Development and Cancers.Curr Protein Pept Sci. 2016, 17(8): 726-734.
10.Du L#,Ning Z#,Zhang H*,Liu F*.Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis.
Chin J Cancer. 2017,36(1):28.
11.Yang Z,Zhang H,Kumar R*.Regulation of E-cadherin. Breast Cancer Online. 2005, 8(03): e15. (Cambridge Univeristy Press, www. camridge. org).
12.Yu Zhou#,Zhimeng Yao,Yusheng Lin,Hao Zhang.From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.Pharmaceutics.2024 Jul 1;16(7):888.
13.Yuhua Meng#,Zhimeng Yao#,Xiurong Ke#,Mengyuan Hu,Hongzheng Ren,Shegan Gao*,Hao Zhang*.Extracellular vesicles-based vaccines:emerging immunotherapies against cancer.Journal of Controlled Release.(已接收）
14.林宇晟, 甘进锋, 江钰琛, 王飞寒, 张灏*: 外泌体标志物和肿瘤液体活检的研究进展及现状。中国癌症防治杂志, 2019, 11(02): 99-103.
15.刘情, 郑琳, 张灏*: 人源性肿瘤组织异种移植(PDX)模型的研究进展。转化医学杂志, 2014, 10. 3969, 2095-3097.
16.黄裔腾, 殷秀凯, 钟雪云, 张灏*: 食管鳞癌模式动物的研究进展。世界华人消化杂志, 2011, 19(16): 1704-1710.
17.李宗泰, 张灏*: 外周血游离DNA甲基化检测: 食管鳞癌早期诊疗的新机遇。转化医学杂志, 2012, 1(1)：45-48.
18.李金平, 宁志丰, 刘复兴, 张灏*: 老药新用, 小分子药物二甲双胍的抗肿瘤研究进展。中国生化药物杂志, 2016 , 36 (8) : 16-21
19.王姝宏，余幼林，李凯，林宇晟，甘进锋，谢飞凌，李勇，黄思铨，张灏*.外泌体在肿瘤和极端条件中的作用和检测。中国癌症防治杂志, 2020, 12(3)：239-243.
20.吴晓，杨海军，高社干，周福有，张灏*. 原发性食管小细胞癌的研究及诊疗现状。食管疾病，2020, 2(1), 8-12.
※专家共识和指南
1.张灏等.《外泌体研究、转化和临床应用专家共识》，转化医学杂志，2018。
2.张灏等.《CSCO胰腺癌指南2024》
※论著摘选(*通讯作者)
学术论文(*通讯作者)
1.Li K#,Lin Y,Luo Y,Xiong X,Wang L,Durante K,Li J,Zhou F,Guo Y,Chen S,Chen Y,Zhang D,Yeung SJ,Zhang H*.A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study.Mol Cancer.2022 Jan 18;21(1):21.
2.Li K#,Lin Y#,Zhou Y,Xiong X,Wang L,Li J,Zhou F,Guo Y,Chen S,Chen Y, Tang H,Qiu X,Cai S,Zhang D,Bremer E,Jim Yeung SC, Zhang H*.Salivary extracellular miRNAs for early detection and prognostication of esophageal cancer: a clinical study.Gastroenterology.2023 Oct;165(4):932-945.e9.
3.Xiong X#,Ke X#,Wang L,Lin Y,Wang S,Yao Z,Li K,Luo Y,Liu F,Pan Y, Yeung SC,Helfrich W,Zhang H*.Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles. J Extracell Vesicles. 2022 Aug;11(8):e12243.
4.Wang L#,Lin Y#,Yao Z#,Babu N,Lin W,Chen C,Du L,Cai S,Pan Y,Xiong X,Ye Q, Ren H,Zhang D,Chen Y,Yeung SJ,Bremer E,Zhang H*.Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases.Drug Resist Updat. 2024 Sep;76:101118.2024.101118.
5.Lin Y#,Dong H#,Deng W#,Lin W,Li K,Xiong X,Guo Y,Zhou F,Ma C,Chen Y,Ren H,Yang H,Dai N,Ma L,Meltzer SJ,Yeung SJ,Zhang H*.Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma. Clin Cancer Res. 2019 May 15;25(10):3035-3045.
6.Xiong X#,Ke X#,Wang L#,Yao Z,Guo Y,Zhang X,Chen Y,Pang CP,Schally AV*,Zhang H*.Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target. Proc Natl Acad Sci USA, 2020, 117(12): 6726-6732.
7.Wang S#,Lin Y#,Xiong X,Wang L,Guo Y,Chen Y,Chen S,Wang G,Lin P,Chen H,Yeung SJ*,Bremer E,Zhang H*.Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer. Clin Cancer Res.2020 Sep 15;26(18):4921-4932.
8.Wang L#,Du L,Xiao X,Lin Y,Zhu J,Yao Z,Wang S,Guo Y,Chen Y,
Geary K,Pan Y,Zhou F,Gao S,Zhang D,Yeung SC,Zhang H*.Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.Oncogene.2021 Mar;40(11):1974-1987.
9.Dong H#,Lin W#,Du L#,Yao Z,Li F,Chen S,Huang Y,Ren H,Luo Y,Cai S, Chen Y, Tang H,Qiu X,Pan Y,Huang X,Zhang D,Gao S*,Yeung SJ*,Zhang H*.PTPRO suppresses lymph node metastasis of esophageal carcinoma by dephosphorylating MET.Cancer letters.2023 Jul 28:567:216283.
10.Dong H#,Ma L#,Gan J,Lin W,Chen C,Yao Z,Du L,Zheng L,Ke C,Huang X,Song H,Kumar R,Yeung SC*,Zhang H*.PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2. Oncogene. 2017 Jan 19;36(3):410-422.
11.Yao Z#,Dong H#,Zhu J#,Du L#,Luo Y#,Liu Q,Liu S,Lin Y,Wang L,Wang S,Wei W,Zhang K,Huang Q,Yu X,Zhao W,Xu H,Qiu X,Pan Y,Huang X,Yeung SC,Zhang D,Zhang H*.Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment. JCI Insight.2023 Jul 24;8(14):e166306.
12.Luo Y#,Du L#,Yao Z,Liu F,Li K,Li F,Zhu J,Coppes RP,Zhang D,Pan Y, Gao S*,Zhang H*.Generation and Application of Inducible Chimeric RNA ASTN2-PAPPAas Knockin Mouse Model.Cells.2022 Jan 14;11(2):277.
13.Yao Z#, Du L#, Xu M, Li K, Guo H, Ye G,Zhang D,Coppes RP, Zhang H*. MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma. Front Oncol. 2019 Aug 27;9:816.
14.Gan J#,Ke X#,Jiang J#,Dong H#, Yao Z,Lin Y,Lin W,Wu X,Yan S, Zhuang Y,Chu WK,Cai R,Zhang X,Cheung HS,Block NL,Pang CP,Schally AV, Zhang H*. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.Proc Natl Acad Sci U S A.2016 Dec 20;113(51):14745-14750.
15.Dong H#,Xu J,Li W,Gan J,Lin W,Ke J,Jiang J,Du L,Chen Y,Zhong X, Zhang D,Yeung SC,Li X,Zhang H*.Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis. J Pathol. 2017 Mar;241(4):448-462.
16.Dong H#,Du L#,Cai S#,Lin W#,Chen C,Still M,Yao Z,Coppes RP,Pan Y, Zhang D,Gao S*,Zhang H*.Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance. Frontiers in Pharmacology.2022 Apr 1;13:838171.
17.Zhu J#,Wang L#,Liu F,Pan J,Yao Z,Lin Y,Yang Y,Xiong X,Li K,Yang Y, Zhang Y,Chu X,Pan Y*,Zhang H*.Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer.Cancers (Basel).2022 Jan 13;14(2):383.
18.Huang J#,Liu D#,Li J,Xu J,Dong S*,Zhang H*.A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.Annals of medicine.2023;55(2):2260387.
19.Ploeg E#,Ke X#,Britsch I,Hendriks M,Van der Zant F,Kruijff S,Samplonius D,Zhang H*,Helfrich W*.Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.Cancer Letters.2021 Aug 28:521:109-118.
20.Dong H, Xie C, Jiang Y, Li K, Lin Y, Pang X, Xiong X, Zheng J, Ke X, Chen Y, Li Y, Zhang H*. Tumor-Derived Exosomal Protein Tyrosine Phosphatase Receptor Type O Polarizes Macrophage to Suppress Breast Tumor Cell Invasion and Migration. Front Cell Dev Biol. 2021 Sep 28;9:703537.
21.Wang L#,Xiong X,Yao Z,Zhu J,Lin Y,Lin W,Li K,Xu X,Guo Y,Chen Y, Pan Y,Zhou F,Fan J,Chen Y,Gao S*,Sai-Ching Jim Yeung,Zhang H*. Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer. Cancer Letters. 2021 Mar 31;501:1-11.
22.Feiling Xie#,Hongmei Dong*,Hao Zhang*.Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells.Frontiers in immunology.Front Immunol.2021 Nov 22:12:783370.
23.Zou X#,Lin Y#,Ren H#,Meng Y,Chen S,Jiang Y,Cui W,Gu Y,Guo L, Yi L,Zhang D, Zhang H*,Wu G*.PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma. Anticancer Res. 2024,44(2):593-604.
24.Cao S#,Wang X#,Liu X,Li J,Duan L,Gao Z,Lun S,Zhu Y,Yang H,Zhang H*,Zhou F*.Integrative Analysis of Angiogenesis-Related Long Non-Coding RNA and Identification of a Six-DEARlncRNA Signature Associated with Prognosis and Therapeutic Response in Esophageal Squamous Cell Carcinoma. Cancers.2022 Aug 30;14(17):4195.
25.Liu S#,Yang P#,Wang L#,Zou X,Zhang D,Chen W,Hu C,Xiao D,Ren H*,Zhang H*,Cai S*.Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress.Cell Death Discov.2024, 10(1):36.
26.Xingli Dong#,Yusheng Lin#,Kai Li,Gaofeng Liang,Xiaoyi Huang,Jingxuan Pan, Lu Wang,Dongmei Zhang, Tingjiao Liu, Tong Wang, Xiaomei Yan, Long Zhang, Xiaowu Li, Xiujuan Qu, Da Jia,Yong Li* and Hao Zhang*.Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine.Clin Chem Lab Med.2024 Jun 19.Clin Chem Lab Med.2024 Jun 19.
27.Ploeg EM#,Ke X#,Britsch I,Hendriks MAJM,Van der Zant FA,Kruijff S, Samplonius DF,Zhang H*,Helfrich W*.Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.Cancer Lett. 2021 Aug 28;521:109-118.
28.Du L#,Wang L#,Gan J#,Yao Z,Lin W,Li J,Guo Y,Chen Y,Zhou F*,Jim Yeung SC,Coppes RP,Zhang D,Zhang H*.MTA3 Represses Cancer Stemness by Targeting the SOX2OT/SOX2 Axis.iScience.2019 Dec 20;22:353-368.
29.Xu B, Jiang X,Xiong J, Lan J,Tian Y,Zhong L,Wang X,Xu N,Cao H, Zhang W,Zhang H, Hong X, Zhan YY*,Zhang Y*,Hu T*. Structure-Activity Relationship Study Enables the Discovery of a Novel Berberine Analogue as the RXRα Activator to Inhibit Colon Cancer. J Med Chem. 2020 Jun 11;63(11):5841-5855.
30.Jinfeng Gan, Hao Zhang*.PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma.Transl Cancer Res.2020;9(8):4800-4810
31.Dong H#,Xie C#,Yao Z#,Zhao R#,Lin Y,Luo Y,Chen S,Qin Y,Chen Y*, Zhang H*.PTPRO-related CD8 + T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer. Front Immunol.2022 Aug 8:13:947841.
32.Bhagelu R.Achyut,Zhang H*,Kartik Angara,Nahid F.Mivechi,Ali S. Arbab,Lan Ko*.Oncoprotein GT198 Vaccination Delays Tumor Growth in MMTV-PyMT Mice. Cancer Lett. 2020, 476:57-66.
33.Achyut BR,Zhang H,Angara K,Mivechi NF,Arbab AS,Ko L. Achyut BR, Zhang H,Angara K,Mivechi NF, Arbab AS, Ko L. Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice. Cancer Lett. 2020 Apr 28;476:57-66.
34.Ke X, Xiong X, Lin Y, Zhang H*.Chimeric RNA and Exosomes-Based Liquid Biopsy. Methods Mol Biol.2020;2079:211-218.
35.Tamiya H#,Kim H#,Klymenko O,Kim H*,Feng Y,Zhang T,Han JY,Murao A,Snipas SJ,Jilaveanu L,Brown K,Kluger H,Zhang H,Iwai K,Ronai ZA*.SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. J Clin Invest.2018 Jan 2;128(1):517-530.
36.Wang W#,Lim KG#,Feng M,Bao Y,Lee PL,Cai Y,Chen Y,Zhang H, Marzese D,Hoon DSB,Yu Q*.KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer. Mol Cancer Ther.2018 Sep;17(9):1973-1983.
37.Wang L,Li K,Lin X,Yao Z,Wang S,Xiong X,Ning Z,Wang J,Xu X,Jiang Y,Liu D,Chen Y,Zhang D,Zhang H*.Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis.Cancer Lett.2019 May 28;450:22-31.
38.Feng Y#,Ke C#,Tang Q#,Dong H,Zheng X,Lin W,Ke J,Huang J,Yeung SC,Zhang H*.Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis.2014 Feb 27;5(2):e1088.
39.Li Z#,Zou X#,Xie L,Chen H,Chen Y,Yeung SC,Zhang H*.Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.Int J Cancer.2015 Apr 1;136(7):1636-45.
40.Zhang H*,Lin W,Kannan K,uo L,Li J,Chao PW,Wang Y,Chen YP,Gu J,Yen L*.Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma. Oncotarget.2013 Nov;4(11):2135-43.
41.Yu J#,Lin Y#,Xiong X#,Li K,Yao Z,Dong H,Jiang Z,Yu D,Yeung SJ,Zhang H*.Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis. Front Genet.2019 Mar 14;10:202.
42.Wang L,Li W,Li K,Guo Y,Liu D,Yao Z,Lin X,Li S,Jiang Z,Liu Q,Jiang Y, Zhang B,Chen L,Zhou F,Ren H,Lin D,Zhang D,Yeung SJ,Zhang H*.The oncogenic roles of nuclear receptor coactivator 1 in human esophageal carcinoma. Cancer Med. 2018 Oct;7(10):5205-5216.
43.Tang Q,Li G,Wei X,Zhang J,Chiu JF,Hasenmayer D,Zhang D,Zhang H*. Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer Lett. 2013 Aug 19;336(2):325-37.
44.You Y,Chen Y,Zheng X,Meltzer SJ,Zhang H*.Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett. 2012 Feb 28;315(2):138-44.
45.Zhang S,Zeng D,Peng Y,Yang Y,Zhuang X,Li Z,Wang M,Chen L,Zhang H*.Cancer-related fatigue and chemotherapy-associated adverse effects: correlation with TNF-α, IL-1 and 17-hydroxycorticosteroids.Future Oncol. 2014;10(9):1619-26.
46.Zhang H,Singh RR,Talukder AH,Kumar R*.Metastatic tumor antigen is a direct corepressor of the Wnt4 pathway.Genes Dev.2006 Nov 1;20(21):2943-8.
47.Zhang H,Kuang SQ,Liao L,Zhou S,Xu J*.Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Cancer Res. 2004 Oct 1;64(19):7169-77.
48.Zhang H,Stephens LC,Kumar R*.Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006 Mar 1;12(5):1479-86.
49.Zhou C*,Wu Y,Chen G,Liu X,Zhu Y,Lu S,Feng J,He J,Han B,Wang J, Jiang G, Hu C,Zhang H,Cheng G,Song X,Lu Y,Pan H,Zheng W,Yin AY. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204.
50.Kumar R*,Zhang H,Holm C,Vadlamudi RK,Landberg G,Rayala SK*. Extranuclear coactivator signaling confers insensitivity to tamoxifen.Clin Cancer Res.2009 Jun 15;15(12):4123-30.
51.Peng M,Zhang H,Jaafar L,Risinger JI,Huang S,Mivechi NF,Ko L*. Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97.
52.Tong Z#,Li M#,Wang W,Mo P,Yu L,Liu K,Ren W,Li W,Zhang H,Xu J, Yu C*.Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/beta-Catenin Signaling. J Biol Chem. 2015 Jul 24;290(30):18596-608.
53.Chu WK,Law KS,Chan SO,Yam JC,Chen LJ,Zhang H,Cheung HS, Block NL,Schally AV*,Pang CP*.Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.Proc Natl Acad Sci USA.2016 Dec 13;113(50):14396-14401.
54.Klionsky DJ, Zhang H et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016, 12(1): 1-222.
55.Chen T,Chen Q,Xu Y,Zhou Q,Zhu J,Zhang H,Wu Q,Xu J,Yu C*.SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.JHepatol.2012 Jan;56(1):210-7.
56.Lin Y#, Choukrani G#, Dubbel L, Rockstein L, Freile JA, Qi Y, Wiersma V, Zhang H, Koch KW, Ammatuna E, Schuringa JJ, van Meerten T, Huls G, Bremer E*. VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.Exp Hematol Oncol. 2024 Mar 29;13(1):35.
57.Ploeg EM*,Samplonius DF,Xiong X,Ke X, Hendriks M,Britsch I,van Wijngaarden AP,Zhang H,Helfrich W*.Bispecific antib ody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.J Immunother Cancer.2023 Sep;11(9):e006837.
1.《肿瘤急症治疗例析》《人民卫生出版社》主编，2023年；
2.《肿瘤标志物》《人民卫生出版社》编委，2022年；
3.《Chimeric RNA: Methods and Protocols》《Springer出版社》编委；
4.《乳腺癌》《人民卫生出版社》副主编，2019年；
5.《细胞外囊泡》《科学出版社》编委，2019年；
6.《Extracellular Vesicles: From Bench to Bedside》编委；
7.《肿瘤标志物通讯》（外泌体专刊）《中国抗癌协会出版》主编，2018年;
8.《Encyclopedia of Cancer 》(癌症百科全书）《Springer出版社》编委，2002年
1.牙龈卟啉单胞菌诱发微生态失衡促进食管癌发生发展的机制及应用，河南省科学技术进步奖，一等奖，2023年；
2.食管癌肿瘤标志物及液体活检的应用与开发，广东省科技厅，广东省科学技术科技进步奖，二等奖，2020年；
3.牙龈卟啉单胞菌促进食管癌发生发展病因的阐明及应用,中华医学会,中华医学科学技术奖三等奖,2023年；
4.液体活检和老药新用诊治食管癌新机制，新靶点和转化研究，广东省医学会，广东省医学会科技进步奖，二等奖，2024年；
5.食管癌早期诊断和治疗新方法的转化研究，广东省医学会，广东省医学会科技进步奖，二等奖，2019年；
6.低剂量二甲双胍重编程食管癌免疫微环境：II期临床研究，Gastroenterology Report,《中华胃肠外科杂志》《中华炎性肠病杂志》联合颁发, 2020年度十佳消化道领域临床研究金奖,2020年；
7.中国产学研合作创新与促进奖，中国产学研合作促进会,2021年；
8.上消化道肿瘤诊断和治疗新方法的转化研究，汕头市科学技术奖励，一等奖，2018年；
9.食管癌化疗敏感性标志物和诊疗新方法的研究及应用，广东省药学会医院药学科学技术奖，一等奖，2020年；
10.食管癌化疗敏感性标志物和诊疗新方法的研究及应用，中国药学会科学技术奖，三等奖，2020年；
11.药物基因组学和纳米载体在肿瘤药物治疗中的应用及评价，广东省优秀科技成果，2019年；
12.《金博奖全球高层人才科技创新大赛金奖》，2021年；
13.《中国研究型医院学会医学研究创新奖一等奖》2022年；
14.《Wiley中国开放科学高贡献奖》2022年；
15.《2022中国生物医药企业最具创新力50强奖》2022年；
指导团队青年成员获得过如下项目:
1. 2020年第三届粤港澳大湾区医学与健康发展论坛获得一等奖
2. 2020年暨南大学生命科学创新奖获得二等奖
3. 2021年第四届粤港澳大湾区医学与健康发展论坛获得二等奖
4. 2021年暨南大学生命科学创新奖获得二等奖
5. 2023年暨南大学第四届“全国大学生基础医学创新研究暨实验设计论坛”中荣获临床医学赛道实验设计组三等奖
6. 2024年暨南大学第五届基础医学创新研究暨实验设计竞赛三等奖
7. 2024年荣获第二届广东省高校实验室安全知识校际邀请赛微视频校内选拔赛二等奖
8. 2024年暨南大学第十二届“挑战杯”大学生创业计划竞赛“获得银奖
1.中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会（CSEMV）主委
2.《外泌体研究转化和临床应用专家共识》专家组组长
3.Annals of Medicine（Taylor & Francis 出版社）肿瘤学主编
4.Cancer Letters（Elsevier 出版社）和Scientific Report（Nature出版社）编委
5.Extracellular Vesicles & Circulating Nucleic Acids&Extracellular Vesicle & 编委
6.Cancer Research，Clinical Cancer Research,Gastroenterology & Journal of Controlled Release & Journal of Pathology & Journal of Extracellular Vesicles & Oncogene & PNAS等杂志的审稿专家
7.《胰腺癌诊治指南》撰写组专家
8.中国抗癌协会肿瘤标志专业委员会常务委员
9.中国抗癌协会肿瘤标志物专业委员会常委
10.中国抗癌协会肿瘤代谢委员会常委
11.中国临床肿瘤协会胰腺癌专家委员会常委
12.亚太医学生物免疫学会肿瘤学分会副主委
13.广东省抗癌协会肿瘤代谢委员会副主委
14.广东省抗癌协会肿瘤标志物专业委员会副主委
15.广东省抗癌协会抗肿瘤药物专业委员会副主委
